In vivo, co-administration of the sh-RPS6KA2 plasmid and cisplatin significantly increased the expression of ATG5, ATG7, and BECN1, as well as promoted subcutaneous tumor growth compared to cisplatin monotherapy (Fig. 8A). This evidence concerns the gene ATG7 and neoplasm.